Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Gasoline Prices Rise 3% as Strait of Hormuz Tensions Threaten Global Fuel Supply

The latest gasoline price rally followed the US launching fresh strikes on Iran, a day after hitting roughly 140 targets in retaliation for an IRGC attack on a container ship transiting the Strait of Hormuz. Iran responded by targeting US military facilities in Jordan, …

Nitish Kishor | 13 July 2026

Forte Biosciences, Inc. (NASDAQ: FBRX): Why High-Severity Vitiligo Patients Are the Real Story Behind FB102's Data

That distinction between p=0.020 for the overall population and p=0.006 for the severe subgroup is not a minor statistical footnote. A lower p-value indicates a stronger, more reliable signal, meaning the effect seen in high-severity patients is even less likely to be attributable to …

Nitish Kishor | 13 July 2026

Forte Biosciences, Inc. (NASDAQ: FBRX): Why Shares Soared 20% on a Single Vitiligo Data Point

Statistical significance matters enormously in a market that has grown skeptical of small-sample, directional-but-inconclusive biotech data. A p=0.020 result tells investors this improvement is unlikely to be noise, and that distinction is often the difference between a stock that drifts and one that reprices …

Nitish Kishor | 13 July 2026

Glucotrack, Inc. (NASDAQ: GCTK): Why This New Patent Allowance Matters for Implantable Glucose Monitoring

To appreciate why this matters, it helps to understand what makes continuous blood glucose monitoring, or CBGM, technically difficult in the first place. Most glucose monitors on the market today are worn externally or use short-term subcutaneous sensors that need regular replacement. Glucotrack is …

Nitish Kishor | 13 July 2026

Merck & Co., Inc. (NYSE: MRK): Why the PADCEV-KEYTRUDA Bladder Cancer Approval Is a Milestone Worth Understanding

Understanding why this combination makes clinical sense requires understanding what each drug does individually. PADCEV is an antibody-drug conjugate, a therapy that combines a targeting antibody with a potent cytotoxic payload, designed to deliver cancer-killing chemotherapy directly and specifically to tumor cells expressing a …

Nitish Kishor | 13 July 2026

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA): Why Early Preclinical Data Could Be a Signal Worth Watching

The specific findings center on three interconnected pharmacological properties: oral bioavailability, systemic exposure, and tissue distribution. Oral bioavailability measures how much of an orally administered drug actually reaches systemic circulation intact, a critical practical consideration since a drug that can't be reliably absorbed through …

Nitish Kishor | 13 July 2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX): Why Completed Phase 1 Enrollment Is a Bigger Deal Than It Looks

It's worth understanding why this stage of development carries real weight even without an accompanying efficacy readout. Dose-escalation enrollment is the process of methodically enrolling patients across a range of drug doses to establish safety, tolerability, and an appropriate dose for further study. Completing …

Nitish Kishor | 13 July 2026

Q32 Bio Inc. (NASDAQ: QTTB): Why Bempikibart Data Sent Shares Up Over 60% in a Single Session

The SALT score quantifies the percentage of scalp hair loss, meaning a mean reduction of this magnitude translates into visible, measurable hair regrowth for trial participants, not just a marginal or cosmetic effect. Layered on top of that headline figure, the trial also reported …

Nitish Kishor | 13 July 2026

Silo Pharma, Inc. (NASDAQ: SILO): Why Shares Fell 26% Right After a Successful Capital Raise

The transaction involved approximately 619,965 common shares or pre-funded warrants, a relatively modest share count on its face. But the real story sits in what came attached to that raise: newly issued Series A-3 and Series A-4 warrants, each exercisable at $6.21 per share. …

Nitish Kishor | 13 July 2026

Tvardi Therapeutics, Inc. (NASDAQ: TVRD): Why a Bullish Piper Sandler Call Didn't Stop Shares From Falling 14%

On paper, this should have been an unambiguously positive day for the stock. Rating upgrades paired with substantial price target increases typically move shares higher, sometimes sharply, as institutional investors and algorithmic screens react to the bullish signal. A jump from $3 to $13 …

Nitish Kishor | 13 July 2026
Support

Hi! How can we help you today?

Loading…